Janet Darbyshire

发表

Global overview of the resurgence of tuberculosis

Janet Darbyshire, 1997 .

0804 PRION-1 TRIAL: Therapies for human prion disease (ISRCTN06722585)

Martin N. Rossor, S Wroe, J Collinge, 2005, Journal of Neurological Sciences.

Is the time from HIV seroconversion a determinant of the risk of AIDS after adjustment for updated CD4 cell counts

Santiago Pérez-Hoyos, J Darbyshire, Andrew N. Phillips, 2001 .

PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial

Sheena McCormack, Helen Rees, Heiner Grosskurth, 2010, The Lancet.

Evidence of a decline in transmitted HIV-1 drug resistance in the United Kingdom

John P. Walsh, Andrew N. Phillips, Steve Kaye, 2007, AIDS.

Data monitoring in randomized controlled trials: surveys of recent practice and policies

Diana Elbourne, Janet Darbyshire, Felicity Clemens, 2005, Clinical trials.

Regulatory impediments jeopardizing the conduct of clinical trials in Europe funded by the National Institutes of Health

Abdel Babiker, Janet Darbyshire, James D Neaton, 2010, Clinical trials.

An evaluation of HIV RNA and CD4 cell count as surrogates for clinical outcome. Delta Coordinating Committee and Virology Group.

Abdel Babiker, Philippe Flandre, Peter Reiss, 1999, AIDS.

Randomised controlled trial of single BCG, repeated BCG, or combined BCG and killed Mycobacterium leprae vaccine for prevention of leprosy and tuberculosis in Malawi

N. Maine, Janet Darbyshire, A. Chihana, 1996, The Lancet.

Determinants of survival following HIV-1 seroconversion after the introduction of HAART

Kholoud Porter, Abdel Babiker, A Sarah Walker, 2003, The Lancet.